Liver Fibrosis Scores and Clinical Outcomes in Patients With COVID-19.

ABSTRACT:

Background and aims

We investigated the association between liver fibrosis scores and clinical outcomes in patients with COVID-19.

Methods

We performed a post-hoc analysis among patients with COVID-19 from the trial study Outcomes Related to COVID-19 treated with Hydroxychloroquine among Inpatients with symptomatic Disease (ORCHID) trial. The relationship between aspartate aminotransferase (AST) to platelet ratio index (APRI), non-alcoholic fatty liver disease fibrosis score (NFS), Fibrosis-4 index (FIB-4), and discharge and death during the 28-days of hospitalization was investigated.

Results

During the 28 days after randomization, 237 (80.6%) patients were discharged while 31 (10.5%) died among the 294 patients with COVID-19. The prevalence for advanced fibro

SUBMITTER: Zhang J 

PROVIDER: S-EPMC9024307 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature